Table 6.
Efficacy outcomes in terms of median overall survival (OS) in atezolizumab randomized trials, according to PD-L1 expression
| Differential populations as for PD-L1 scoring | OAK21 | Poplar19 | IMpower150 (WT population)a,24 | IMpower131a,27 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atezo (months) | Doc (months) | HR P-value | Atezo (months) | Doc (months) | HR P-value | ABCP (months) | BCP (months) | HR P-value | ACnP (months) | CnP (months) | HR P-value | |
| ITT (n) pts |
13.3 613 |
9.8 612 |
0.80 0.0012 |
12.6 144 |
9.7 143 |
0.69 0.011 |
19.2 359 |
14.7 337 |
0.78 0.02 |
14.0 343 |
13.9 340 |
0.96b 0.6931 |
| TC3 or IC3 pts |
20.5 89 (14%) |
9.7 85 (14%) |
0.45 ,0.0001 |
NR 24 (17%) |
11.1 23 (16%) |
0.45 0.033 |
25.2 | 15 | 0.70b | 23.6 53 (15%) |
14.1 48 (14%) |
0.56 |
| 136 (20%) | ||||||||||||
| TC2/3 or IC2/3 pts |
16.6 168 (27%) |
11.4 182 (30%) |
0.64 0.0012 |
15.1 50 (35%) |
7.4 55 (38%) |
0.50 0.003 |
NA | NA | NA | NA | NA | NA |
| TC1/2/3 or IC1/2/3 pts |
14.3 347 (57%) |
10.8 337 (55%) |
0.77 0.0045 |
15.1 93 (65%) |
9.2 102 (71%) |
0.59 0.003 |
NA | NA | NA | NA | NA | NA |
| TC2 or IC2 pts |
12.6 | 13 | 0.98b | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 177 (14%) | ||||||||||||
| TC1/2 or IC1/2 pts |
NA | NA | NA | NA | NA | NA | 20.3 | 16.4 | 0.80b | 12.4 129 (38%) |
16.6 121 (36%) |
0.70 |
| 226 (32%) | ||||||||||||
| TC0/1/2 or IC0/1/2 pts |
NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| TC1 or IC1 pts |
12.7 | 9.7 | 0.87b | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 334 (27%) | ||||||||||||
| TC0 and IC0 pts |
11.8 260 (42%) |
8.9 271 (44%) |
0.84b 0.0887 |
9.7 51 (35%) |
9.7 41 (29%) |
0.88b 0.601 |
17.1 | 14.1 | 0.82b | 13.8 160 (47%) |
12.5 171 (50%) |
0.81b |
| 339 (49%) | ||||||||||||
Notes:
a
Preliminary results with regard to OS, given the limited follow-up.
b
95% confidence interval (95% CI) crossing the unit.
Abbreviations: ABCP, atezolizumab, bevacizumab, carboplatin, paclitaxel; AcnP, atezolizumab, carboplatin, nab-paclitaxel; Atezo, atezolizumab; BCP, bevacizumab, carboplatin, paclitaxel; CnP, carboplatin, nab-paclitaxel; Doc, docetaxel; HR, hazard ratio; ITT, intention to treat; NA, not available; pts, number of patients; TC, tumor cell; IC, immune cell; WT population, including only EGFR and ALK wild-type patients.